Remuneration policy
Remuneration to Board of Directors
Fees are payable to the Chairman of the Board of Directors and other directors pursuant to a resolution adopted by the AGM.
The Annual General Meeting 2026 resolved that the fees for the Board of Directors, for the period until the end of the next Annual General Meeting, shall be SEK 900,000 in cash and SEK 450,000 in Restricted Share Units (“RSUs”) to the chair of the Board and SEK 400,000 in cash and SEK 200,000 in RSUs each to the other Board members. It was further resolved that the remuneration to the chair of the Audit Committee should be SEK 150,000 and SEK 75,000 to each other member in the Audit Committee, SEK 50,000 to the chair of the Remuneration Committee and SEK 25,000 to each other member in the Remuneration Committee. Each Board member residing outside of Europe shall also receive SEK 150,000 for travel compensation. Natalie Berner and Michael Bologna have declined to receive Board remuneration.
Documents
Remuneration to CEO
In 2024, the CEO received a total of KSEK 14,101 in salaries, bonuses and other benefits.
If notice of termination of employment is made by the Company, the notice period may not exceed six months. Fixed cash salary during the period of notice and any severance pay may together not exceed an amount equivalent to the fixed cash salary for 18 months for the CEO, i.e. 6 plus 12 months.
The CEO is responsible for their pension provision, thus the Company has no direct pension cost for the CEO.
Documents
Auditors and their compensation
KPMG and Azets are providing audit services on behalf of Hansa Biopharma. The fee for auditing services for the Group were KSEK 2,709 in 2024. Audit services refer to the legally required examination of the annual report and the book-keeping.
Documents